Get the Stockscreener App
0.9714
1.00%
-0.0286
Tiziana Life Sciences Ltd stock is traded at $0.9714, with a volume of 45,121.
It is down -1.00% in the last 24 hours and up +14.46% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$1.00
Open:
$0.99
24h Volume:
45,121
Relative Volume:
0.18
Market Cap:
$102.10M
Revenue:
-
Net Income/Loss:
$-19.50M
P/E Ratio:
-6.3908
EPS:
-0.152
Net Cash Flow:
$-19.09M
1W Performance:
+7.11%
1M Performance:
+14.46%
6M Performance:
+20.73%
1Y Performance:
+70.72%
1-Day Range:
$0.95
$0.99
1-Week Range:
$0.875
$1.07
52-Week Range:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TLSA | 0.99 | 102.10M | 0 | -19.50M | -19.09M | -0.152 |
| VRTX | 446.82 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.18 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.10 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.38 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.30 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences secures grant for ALS trial - Proactive financial news
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - The Manila Times
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - GlobeNewswire Inc.
Tiziana reports progress in obesity inflammation study By Investing.com - Investing.com South Africa
Tiziana Life Sciences : announces plans for clinical development of foralumab, the company’s fully human CD3 antibody - Marketscreener.com
Tiziana Life Sciences' Semaglutide combo shows potential in obesity-related liver inflammation - Proactive Investors USA
TLSATiziana Life Sciences Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity - Proactive Investors UK
Tiziana reports progress in obesity inflammation study - Investing.com
Proactive news headlines: Helix, Hemogenyx, DEC, Ananda, Thor Energy, Bradda Head and more - Proactive Investors UK
Discover October 2024's Promising US Penny Stocks - Simply Wall St
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Advances with Promising Drug Trials - Yahoo Finance
Tiziana Life Sciences reports interim results, updates on programs - Investing.com India
Tiziana Life Sciences reports interim results, updates on programs By Investing.com - Investing.com Canada
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
High Affinity Nerve Growth Factor Receptor Market constantly growing to See Bigger Picture - IndiaPolitics.com
Thymic Carcinoma Treatment Market Size, Market Resilience and Forecasted Scenarios (2024-2034) - Third Eye News
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Declines By 67.0% - MarketBeat
Base Resources Limited (OTCMKTS:BSRUF) Sees Significant Increase in Short Interest - Defense World
Tiziana Life Sciences Secures $4M Grant for Alzheimer’s Disease Study - European Pharmaceutical Manufacturer
EverSource Wealth Advisors LLC Acquires 330,000 Shares of Signing Day Sports, Inc. (NYSEAMERICAN:SGN) - Defense World
New Pacific Mtl to Post Q1 2025 Earnings of $0.00 Per Share, Raymond James Forecasts (TSE:NUA) - Defense World
iShares ESG Aware MSCI USA ETF (NASDAQ:ESGU) Stock Holdings Lifted by Affinity Capital Advisors LLC - Defense World
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Affinity Capital Advisors LLC Has $4.62 Million Position in Vanguard Short-Term Bond ETF (NYSEARCA:BSV) - Defense World
ENN Energy Holdings Limited (OTCMKTS:XNGSY) Short Interest Up 550.0% in September - Defense World
Thrivent Financial for Lutherans Cuts Holdings in Regal Rexnord Co. (NYSE:RRX) - Defense World
AlTi Global Inc. Sells 1,052 Shares of CVS Health Co. (NYSE:CVS) - Defense World
Tiziana Life Sciences Ltd: Analyzing TLSA Stock Trends - The InvestChronicle
JPMorgan Chase & Co. Initiates Coverage on Alcoa (NYSE:AA) - Defense World
Tesla's Massive October Starts Next Week With Third-Quarter Deliveries - MSN
CRH plc (NYSE:CRH) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Increase in Short Interest - Defense World
Tesla's Robotaxi Launch: A Game-Changer For Stock Performance? - MSN
Tesla (TSLA) call put ratio 2.1 calls to 1 put with focus on October 285 and 325 calls into deliveries release for Q3 and Robotaxi meeting - StreetInsider.com
Commonwealth Financial Services LLC Acquires 95 Shares of Tesla, Inc. (NASDAQ:TSLA) - Defense World
Tesla: stock outperforms, buoyed by optimism from UBS - Marketscreener.com
Analysts praise groundbreaking Tesla rival, previews Robotaxi event - MSN
Tesla Stock Pops 5% To 2-Month High As Q3 Deliveries, Robotaxi Event Await - MSN
Edge Capital Group LLC Acquires New Holdings in Tesla, Inc. (NASDAQ:TSLA) - Defense World
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):